PapersPMID:17898352
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“There were no significant differences in change in the SANS total score between glycine and placebo subjects or D-cycloserine and placebo subjects.”
- Study
- RCT
- Duration
- 4 months
- Population
- Inpatients and outpatients with schizophrenia or schizoaffective disorder and moderate to severe negative symptoms, adjunctive glycine against placebo; the D-cycloserine arm is a separate comparison against the same placebo
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- inpatients and outpatients with schizophrenia or schizoaffective disorder and moderate to severe negative symptoms
- Participants
- 157
- Comparator
- placebo
- Duration
- 112 days
- Endpoints measured
- 6
- Declined
- this platform holds no node for the endpoint
glycine